AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05220215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic Hamstring Exercise
Description: To perform Nordic Hamstring Exercise, the subject was in kneeling position on the mat, arms by the side or in front of the chest, knee in 90-degree flexion and ankles well stabilized with the help of a therapist which is positioned behind the subject. Then subject was asked to lean forward by using the hamstring muscles by extending while trying to resist the forward fall, he should lean forward from the knee and not from the hip. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and them repeat the procedure again.
Study NCT05220215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hamstring Curl with Resistance band
Description: Traditional Hamstring Curl by using Resistance band.~Resistance Band: Thera-band Green, 4.6 kg resistance at 100% elongation
Study NCT04720014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART-3RP Group Intervention
Description: Nine 1.5 hour group sessions focusing on developing:~1. an understanding of stress physiology and the physiology of the relaxation response;~2. a regular practice of eliciting the relaxation response; and~3. cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice.
Study NCT05814211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device - newly developed intermittent catheter
Description: Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
Study NCT05814211 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator device #1 - SpeediCath Eve
Description: During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use.
Study NCT05814211 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator device #2 - SpeediCath Compact Plus Female
Description: During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use.
Study NCT01964937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123
Description: The DNA-HIV-PT123 (containing clade C ZM96 gag and gp140 along with CN54 pol-nef) will be administered at a dose of 4 mg IM.
Study NCT01964937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT1
Description: The NYVAC-HIV-PT1 vaccine (containing clade C ZM96 gp140) will be administered at a dose of greater than or equal to 5×10\^6 plaque-forming units (PFU)IM, for a planned maximum dose of 1.2×10\^8 PFU.
Study NCT01964937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT4
Description: The NYVAC-HIV-PT4 vaccine (containing ZM96 gag-CN54 pol-nef) will be administered at a dose of greater than or equal to 5×10\^6 PFU IM, for a planned maximum dose of 1.1×10\^7 PFU.
Study NCT01964937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E®
Description: The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.
Study NCT01964937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo vaccine
Description: The placebo vaccine contains sodium chloride for injection USP, 0.9% and will be administered as a 1 mL injection IM.
Study NCT05519371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: During induction of anesthesia, the rimazolam group was given rimazolam pumped at a rate of 12 mg/kg/h~During the maintenance phase of anesthesia, the rimazolam group was given 1.0-2.0 mg/kg/h of rimazolam continuously pumped.
Study NCT05519371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: During induction of anesthesia, propofol 2mg/kg was given, and during the maintenance phase of anesthesia, propofol 6-8mg/kg/h was given as a continuous pump.
Study NCT06233734 — intervention group
Intervention type: DEVICE
Intervention: The Lokomat (Hocoma, Zurich, Switzerland).
Description: The Lokomat is a device which can be used to implement robot-assisted gait training safely within disabled stroke populations. The robot-assisted gait training group will receive training via the Lokomat. Involvement in the study will not influence the duration or frequency of robot-assisted gait training sessions they receive. The amount of training they receive via the Lokomat will be determined (as per standard care) by the care team at the stroke ward.
Study NCT05339477 — intervention group
Intervention type: OTHER
Intervention: Accelerometer measurement
Description: Study personnel will initiate an accelerometer and inform the patient to wear the accelerometer with an elastic belt on their right hip during waking hours for seven consecutive days. Moreover, patients are instructed to register their wear time in an activity diary in paper form. In addition, patients will register their working hours, if relevant. After seven days, patients send back the accelerometer and diary in a pre-paid envelope. The same procedure is repeated at the second follow-up visit at 1 year.
Study NCT05234320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CG-SpikeDown, intranasal formulation
Description: The CG-SpikeDown peptide produces a dose-dependent increase in binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and a dose-dependent inhibition of SARS-CoV-2 protein binding to ACE2, the key cellular target. A similar inhibition of binding to ACE2 in human alveolar basal epithelial cells has been demonstrated.
Study NCT05234320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-SpikeDown, intranasal formulation
Description: The CG-SpikeDown peptide produces a dose-dependent increase in binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and a dose-dependent inhibition of SARS-CoV-2 protein binding to ACE2, the key cellular target. A similar inhibition of binding to ACE2 in human alveolar basal epithelial cells has been demonstrated.
Study NCT05234320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle (Placebo)
Description: patients will receive active drug or placebo in addition to standard of care
Study NCT05234320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of core (type of therapy is depend of decide of the site)
Description: patients will receive active drug or placebo in addition to standard of care
Study NCT06178159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Injection
Description: 2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
Study NCT06178159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab Injection
Description: Initial dose 840mg, after 2nd dose 420mg intravenous infusion， every 3 weeks
Study NCT06178159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3.0 mg/kg, intravenous infusion, D1, every 2 weeks
Study NCT04758663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap/wake conditions on memory
Description: Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities.
Study NCT04758663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap/wake conditions on overnight physiology
Description: Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities. On the nights of the nap and wake conditions, physiology will be recorded in habitual and non-habitual nappers.
Study NCT05391711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Smart Relationships
Description: Mentors assigned to the intervention will receive the following trainings and support:~1. Online Justice, Equity, Diversity, and Inclusion (JEDI) trainings (self-paced)~2. Culturally Smart Relationships Training (live, virtual)~3. JEDI enhanced monthly supervision from case managers~4. Monthly emails with activity suggestions for mentors and youth
Study NCT05547334 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Inference Based Approach (IBA)
Description: The Inference Based Approach (IBA) (as described by Visser et al., 2015 and adapted for use in adolescents by L. Webers)is a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly and carried out as specified in a Dutch session-by-session IBA protocol, containing standardized forms for exercises and homework assignments. Each session has a standard format, starting with agenda setting and evaluating homework assignments, followed by determining and executing a new exercise and determining new homework. The IBA model is based on the assumption that adolescents with OCD and poor inside misjudge the actual state of affairs. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the childs attention from observable reality.
Study NCT06046716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful compassion based on behavioural change taxonomy experimental group
Description: Since this is a waitlist control study both groups get the same intervention. This is a mindful compassion intervention which is based on the behavioural change taxonomy techniques to support the reliability of the intervention. This will include sensate, mindful exercises, relaxation and attending to the critical voice. The intervention consists of behavioural, cognitive and mindful compassion constructs.
Study NCT06046716 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindful compassion based on behavioural change taxonomy experimental group
Description: Since this is a waitlist control study both groups get the same intervention. This is a mindful compassion intervention which is based on the behavioural change taxonomy techniques to support the reliability of the intervention. This will include sensate, mindful exercises, relaxation and attending to the critical voice. The intervention consists of behavioural, cognitive and mindful compassion constructs.
Study NCT06552858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: 150mg oral bid. A PARP inhibitor that mainly exerts its inhibitory effect on tumor cells by inhibiting DNA repair.
Study NCT06552858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: 150mg oral qd d1-21, q4w. Inhibitor of Cyclin D-CDK4/6 that can inhibit the cell cycle, thereby inducing cell apoptosis.
Study NCT04347317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity IMT
Description: The control group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 30% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity.
Study NCT04347317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Intensity IMT
Description: The experimental group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 60% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity.
Study NCT05140239 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Non Interventional
Study NCT05392894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical stem cell transplantation
Description: Stem cell transplant from bone marrow or peripheral blood from haploidentical donor using standard nationally approved transplant procedure.
Study NCT05392894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care may include any currently available therapies for SCD patients. These may or may not include regular elective transfusion therapy or medications such as hydroxycarbamide.
Study NCT04681196 — intervention group
Intervention type: OTHER
Intervention: patients shifted to nasal mask after persistent OSA with oronasal mask
Description: In this group were selected OSA patients exhibiting persistent obstructive events and paradoxical obstruction with oronasal masks during CPAP , that were fully recovered (no more OSA detected) with the shift to nasal one
Study NCT05684146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emboliner Embolic Protection
Description: Emboliner Embolic Protection Device will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
Study NCT05684146 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Cerebral Protection
Description: The Sentinel Cerebral Protection System will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
Study NCT05964686 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group (NaOCl/EDTA)
Description: conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
Study NCT05964686 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dual laser group (Er,Cr:YSGG/Diode):
Description: Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection
Study NCT05964686 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined group (EDTA/Diode):
Description: 17% EDTA was used to remove smear layer followed by diode laser for disinfection
Study NCT05001464 — intervention group
Intervention type: DEVICE
Intervention: reflectance pulse oximeter
Description: Wearing reflectance pulse oximeter at the same time on the night of PSG examination
Study NCT06209801 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: 60 seconds of intervention
Study NCT06209801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: 60 seconds of intervention
Study NCT06209801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical stimulation
Description: 60 seconds of intervention
Study NCT06209801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: 60 seconds of intervention
Study NCT06209801 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor imagery
Description: 60 seconds of intervention
Study NCT06209801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: 60 seconds of intervention
Study NCT05755100 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: I MOVE!+UP
Description: An individual psychotherapy that integrates behavioral weight management with evidence-based psychotherapy for PTSD (Cognitive Processing Therapy) for up to 6 months, augmented with evidence-based psychiatric and weight management medication management.
Study NCT05657795 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Closed-loop automated oxygen control (Oxygenie, SLE6000)
Description: The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
Study NCT05158153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ORKID Bundled Intervention
Description: During the 90-day study period, participants will be prescribed outpatient hemodialysis with cooled dialysate (35-36°C), high sodium dialysate (145 mmol/L), a high ultrafiltration hold threshold (systolic blood pressure > 110 mmHg; ultrafiltration hold threshold will not be applied in participants with baseline systolic blood pressure \< 120 mmHg), and high dose diuretics (160 mg oral furosemide twice daily) to be taken every day at home will also be prescribed. Dialysis will be weaned according to an active weaning protocol.
Study NCT05158153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 160 mg oral furosemide twice daily to be taken every day at home
Study NCT05247619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin
Description: Tisleliumab 200mg, Bevacizumab 7.5mg/kg, Paclitaxel 175mg/m2, and Cisplatin 50mg/m2 (or Carboplatin AUC5) IV on day 1 of every 21-day cycle.
Study NCT06676644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvanted
Description: adjuvanted (aIIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions
Study NCT06676644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-adjuvanted
Description: non-adjuvanted (IIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions
Study NCT06677606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG block
Description: The ultra sound transducer will be placed in a transverse orientation, medial and caudal to the anterosuperior iliac spine in order to identify the anteroinferior iliac spine, the iliopubic eminence and the psoas tendon. Using an in-plane technique and a lateral-to-medial direction, the block needle will be advanced until its tip will be positioned on the periosteum dorsal to the psoas tendon. The LA (20mL of bupivacaine 0.5%) will be injected following negative aspiration.. The accurate position of the needle was confirmed by hydro dissection and spread under the illo-psoas muscle
Study NCT06677606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PAI block
Description: LA infiltration will be carried out using a total dose of 150mg of bupivacaine and a total volume of 60mL. The admixture (consisting of 60mL of bupivacaine 0.25% and 30mg of ketorolac) will be loaded into two 30mL syringes at the beginning of surgery. After insertion of the acetabular component (and before insertion of the femoral stem), the surgeon will infiltrate the deep tissues (ie, anterior and posterior capsules, gluteus minimus and medius muscles, supraacetabular region, area around the anterior inferior iliac spine, and quadratus femoris muscle all the while avoiding the deep hip external rotator muscle group in order to prevent sciatic nerve block) with the first 30mL syringe. Before wound closure, the gluteus maximus muscle, iliotibial band, subcutaneous tissues, and skin will be infiltrated with the second 30mL syringe.
Study NCT06676865 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: the palm print test
Description: The patient's dominant hand was pressed firmly against a blue ink pad, then onto a white sheet of paper without applying body weight. The palm prints were scored as follows:~* Grade 0: All phalangeal areas visible~* Grade 1: Deficiency in the interphalangeal areas of the 4th and 5th digits~* Grade 2: Deficiency in the interphalangeal areas of the 2nd to 5th digits~* Grade 3: Only the tips of the digits visible The palm print test was scored from 0 to 3. Grades 2 and 3 were considered indicators of difficult intubation.
Study NCT06676956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Order of bronchoscopy procedures for peripheral nodule biopsy
Description: Patient scheduled to undergo peripheral nodule biopsy of the lung under bronchoscopy typically get both a nodule biopsy as well as a linear EBUS of the lymph nodes to assess for any disease spread. This procedure will randomize patients to either getting the peripheral nodule first or linear EBUS of the lymph nodes first and assess overall diagnostic yield as the primary outcome.
Study NCT05799963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioMatrix Alpha
Description: Patient will be treated with BioMatrix Alpha
Study NCT06676371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hemiarch replacement
Description: Conventional open hemiarch replacement